التفاصيل البيبلوغرافية
| العنوان: |
Clinical and radiological pattern of olaparib-induced interstitial lung disease. |
| المؤلفون: |
Brudon, Alexandre, Fournier, Dorine, Selle, Frédéric, Seront, Emmanuel, Conforti, Rosa, Veyrac, Gwenaëlle, Gouraud, Aurore, Lebrun-Vignes, Bénédicte, Khalil, Antoine, Zalcman, Gérard, Gounant, Valérie |
| المصدر: |
BMC Pulmonary Medicine; 9/13/2024, Vol. 24 Issue 1, p1-10, 10p |
| مصطلحات موضوعية: |
PULMONARY fibrosis, HYPERSENSITIVITY pneumonitis, JAPANESE people, PNEUMONIA, SMOKING |
| مستخلص: |
Background: PARP inhibitors (PARPi) are used in the treatment of ovarian, breast, pancreatic, and prostate cancers. Pneumonitis has been identified as a potential side effect, with a higher meta-analysis-assessed risk for olaparib versus other PARPi. Olaparib-induced interstitial lung disease (O-ILD) was first described within the Japanese population, with few information available for Caucasian patients. Methods: We performed a retrospective study by pooling data from the French and Belgian pharmacovigilance databases from 2018 to 2022. Patients with O-ILD were included following a central review by: 1) pharmacologists using the French drug causality assessment method; 2) senior pneumologists or radiologists, using the Fleischner Society's recommendations. Results: Five patients were identified and analysed. All were females, with ovarian or breast cancer. Median age at O-ILD diagnosis was 71 (38–72) years old, with no smoking history. Median delay between treatment initiation and symptom occurrence was 12 (6–33) weeks. Pneumonitis severity assessed using the Common Terminology Criteria for Adverse Events V5 was Grade 3 (n = 4) or 2 (n = 1). CT-scan review (n = 3) described hypersensitivity pneumonitis reaction as a common pattern. Bronchioalveolar lavage (n = 4) revealed lymphocytic alveolitis. Treatments relied on olaparib discontinuation (n = 5) and glucocorticoid intake (n = 4), with no fatal issue. Safe re-challenge with PARPi occurred in two patients. Forty additional O-ILD cases were identified in the WHO VigiBase database, including one fatal case. Conclusions: PARPi-ILD is a rare but potentially life-threatening disease, presenting as a hypersensitivity pneumonitis pattern within 3 months of PARPi initiation. Treatment primarily relies on medication discontinuation. Re-challenging with another PARPi could be considered. Clinical trial number: CEPRO #2023–010. [ABSTRACT FROM AUTHOR] |
|
Copyright of BMC Pulmonary Medicine is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Find this article in full text from Springer Verlag. 
Full Text Finder